UBS Strongly Resets Lilly Stock Target

The pharmaceutical giant Eli Lilly has been riding high lately, with analysts scrambling to raise their price targets for the company’s shares. The latest move by UBS setting a $1,425 target is just the latest example of this trend. However, beneath the surface, warning signs are emerging that the bull run may be coming to an end.

Lilly’s growth has been driven in part by its diabetes and obesity treatments, Mounjaro and Zepbound. These drugs have seen impressive revenue increases: $8.66 billion from Mounjaro worldwide, more than doubling from the same period last year, and $4.16 billion from U.S. Zepbound sales, up 80%.

However, one of Lilly’s most anticipated treatments, Foundayo, is facing challenges. Weekly prescriptions for the oral GLP-1 pill have been flat for five weeks, raising questions about its long-term prospects.

In addition to concerns over Foundayo, Lilly’s Alzheimer’s treatment, Kisunla, is still in its early stages and won’t contribute significantly to revenue anytime soon. Meanwhile, the stock itself has struggled to keep pace with analysts’ optimism, closing at $1,152.54 on July 14, down 4.89% over five trading days.

For investors, this development serves as a reminder that even in the hot tech and pharma spaces, there are no guarantees of success. With Lilly set to report its second-quarter results on August 5, now is the time to be watching closely. Will Foundayo finally take off, or will Mounjaro’s international momentum slow down? Can volume continue to outrun prices?

Six banks have raised their targets for Lilly this month, but the stock is already 8% off its high. At a price-to-earnings ratio of over 40, investors are paying for years of growth that hasn’t yet arrived. A lagging sales number can move the shares, but it’s also a reminder that even in the best of times, no stock is immune to setbacks.

Lilly’s bull run may be a cautionary tale about the dangers of following the herd. As investors, we’d do well to remember that there are always multiple sides to every story – and sometimes, it takes a closer look to see what’s really going on beneath the surface.